March 2020


Journal of Cataract & Refractive Surgery
In the journal: March 2020

Photorefractive intrastromal crosslinking (PiXL) for treatment of low myopia: clinical outcomes using transepithelial approach with supplemental oxygen

Gitansha Shreyas Sachdev, MS, Shreyas Ramamurthy, MS, Dandapani Ramamurthy, MD
Crosslinking, most commonly used for stopping progression of keratoconus, could also be used to correct refractive error. A prospective, interventional case series out of Coimbatore, India, evaluated the safety and efficacy of epithelium-on PiXL in 50 eyes of 26 patients. Ultraviolet-A light was delivered using an accelerated, pulsed approach for a total fluence of 15 J/cm2 and supplemental oxygen was incorporated. The researchers saw a significant improvement in UDVA from baseline (logMAR 0.63±0.25) at 3 and 6 months (logMAR 0.08±0.15 and logMAR 0.13±0.18, respectively). There was also significant keratometric flattening, and the correlation between change in MRSE and preop corneal biomechanics was significant. No significant endothelial cell loss or adverse events occurred. The study authors described the change in MRSE and keratometric flattening as greater compared to other crosslinking protocols for myopia, including an epithelium-off approach.

Photorefractive intrastromal corneal crosslinking (PiXL) for correction of hyperopia – 12-month results

Pavel Stodulka, MD, Halasova Zuzana, MD, Slovak Martin, PhD, Sramka Martin, ME, Liska Karel, MSc, Jaroslav Polisensky, MD
A prospective, single-center study from researchers in the Czech Republic shows PiXL as a “promising alternative to conventional laser refractive surgeries for low hyperopia.” The study included 22 eyes with low hyperopia; each received PiXL per the standard protocol. At 12 months postop, manifest refraction had decreased from a median of +0.75 D preoperatively (from a range of +0.63–1.06 D) to a median of +0.25 D (from a range of 0–0.5 D). Seventy-seven percent of eyes were within 0.5 D of emmetropia at 1 month postop, and stability continued out to 12 months. Endothelial cell density was stable, and patients reported low incidence of postop pain and dry eye. The study authors recommend further studies to optimize treatment parameters for different refractive errors and to improve precision of the procedure.

Visual outcome, optical quality, and patients’ satisfaction with a new monofocal intraocular lens, enhanced for intermediate vision: preliminary results

Rita Mencucci, MD, Michela Cennamo, MD, Daniel Venturi, MD, Roberto Vignapiano, MD, Eleonora Favuzza, MD
Two monofocal IOLs—the Tecnis ZCB00 and Tecnis Eyhance ICB00 (both Johnson & Johnson Vision)—were compared in a prospective case series at the University of Florence, Italy. Patients had less than 0.75 D corneal astigmatism and were free from ocular comorbidities. There were 40 eyes (20 patients) in each group. Monocular and binocular distance and near visual acuities were similar, but uncorrected intermediate vision was significantly higher in the Eyhance group. Patients achieved more spectacle independence for intermediate vision with the Eyhance IOL. There was no significant difference in the two groups for contrast sensitivity, objective scatter index, modulation transfer function cut-off, Strehl ratio, or glare and halo perception.

Journal of Cataract & Refractive Surgery In the journal: March 2020 Journal of Cataract & Refractive Surgery In the journal: March 2020
Ophthalmology News - EyeWorld Magazine
283 110
283 110
True, 3